Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations analyze uncovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://michaelk653ill4.bloggosite.com/profile